Investment Thesis
MacroGenics is a pre-profitability pharmaceutical company with minimal revenue ($20.8M) unable to cover operating expenses (-$33.4M), resulting in severe operating losses and negative free cash flow (-$36.2M). With only ~$66.5M in cash against an annual burn rate of ~$36M and no clear path to profitability, the company faces a critical liquidity crisis within 18-24 months without successful drug commercialization or significant capital infusion.
Strengths
- Adequate liquidity position with $66.5M cash providing operational runway
- Solid current ratio (1.90x) and quick ratio (1.80x) indicate short-term solvency
- Low long-term debt burden reduces financial risk relative to liabilities
Risks
- Extreme cash burn rate ($36.2M FCF burn vs $66.5M total cash = ~18-month runway)
- Massive operating losses (-$33.4M) on minimal revenue ($20.8M) indicates business model is not viable at current scale
- Liabilities ($196.7M) constitute 90% of total assets with equity cushion only $21.2M; vulnerability to capital structure failure
- Negative interest coverage (-6.8x) and stagnant revenue growth (-0.3% YoY) indicate deteriorating operational health
Key Metrics to Watch
- Cash burn rate trend and time-to-runway calculation
- Revenue growth rate - any acceleration would indicate product commercialization progress
- Operating loss reduction - path to gross margin breakeven on current revenue
- Capital raise events - next financing round size and dilution terms
Financial Metrics
Revenue
20.8M
Net Income
-36.8M
EPS (Diluted)
$-0.58
Free Cash Flow
-36.2M
Total Assets
217.9M
Cash
66.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-161.0%
Net Margin
-177.0%
ROE
-173.5%
ROA
-16.9%
FCF Margin
-174.0%
Balance Sheet & Liquidity
Current Ratio
1.90x
Quick Ratio
1.80x
Debt/Equity
0.00x
Debt/Assets
90.3%
Interest Coverage
-6.84x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:47:59.389876 |
Data as of: 2026-03-31 |
Powered by Claude AI